Moreover, the regulatory mechanism through which VM were modulated by Rictor in melanoma cells was consistent with AKT inhibition by MK‐2206, the first allosteric small‐molecule inhibitor of AKT to enter clinical development 32, 33. The gene discussed is AKT1; the disease is melanoma.